Eris Lifesciences share news, announcements and annual reports
NSE: ERISBSE: 540596Pharmaceuticals & BiotechnologySmall Cap
Eris Lifesciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2017 · Issue price ₹603
Last close ₹1,156.40down ₹7.20 (0.62%)BSE ₹1,159.60
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,163.60.
30 Oct: open ₹1,163.00, high ₹1,174.70, low ₹1,148.00
52-week range of traded prices to 30 Oct 2026
₹1,069.00Low, 26 Oct 2026₹1,740.00High, 9 Dec 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,044 Cr353rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.67
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.87
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.62%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 19.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 31,21340.7% delivered
Eris Lifesciences disputes and clarifications
17 filed, newest first.
May 2026
28 May · Legal
Feb 2026
28 Feb · Legal
Aug 2025
Mar 2025
20 Mar · Legal
The exchange asked on 20 Mar 2025
Oct 2022
13 Oct · Legal
The exchange asked on 13 Oct 2022
Dec 2021
29 Dec · Legal
The exchange asked on 28 Dec 2021
Jul 2021
2 Jul · Legal
The exchange asked on 1 Jul 2021
Jun 2020
16 Jun · Legal
The exchange asked on 15 Jun 2020
Apr 2020
17 Apr · Legal
The exchange asked on 16 Apr 2020
Dec 2019
6 Dec · Legal
Significant increase in volume has been observed in Eris Lifesciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Feb 2018
19 Feb · Legal
Exchange has sought clarification from Eris Lifesciences Limited with respect to announcement dated 13-Feb-2018, regarding " Eris Lifesciences Limited has informed the Exchange regarding Change in Auditors of the company.-Internal auditor". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Nov 2017
22 Nov · Legal
Exchange has sought clarification from Eris Lifesciences Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Reconciliation of profit and loss not submitted The response of the Company is awaited.
Sep 2017